Endorecherche. Inc.
Records under this name other than the patents Endorecherche. Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,629,129 | Pharmaceutical Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 10,881,650 | Pharmaceutical Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 8,957,054 | Pharmaceutical Compositions Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,835,413 | Sex Steroid Precursors Alone or in Combination with a Selective Estrogen Receptor Modulator And/Or with Estrogens And/Or a Type 5 CGMP Phosphodiesterase Inhibitor for the Prevention and Treatment of Vaginal Dryness and Sexual Dysfunction in Postmenopausal Women Formerly held In force · High confidence | In force | High confidence | |
| US 8,268,806 | Pharmaceutical Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 11,452,731 | A Method of Treating and Preventing Loss of Cognition Lapsed on the fee record Ended Sep 27, 2026 · High confidence | Lapsed on the fee record | Ended Sep 27, 2026 | High confidence |
| US 10,076,525 | Sex Steroid Precursors Alone or in Combination with Selective Estrogen Receptor Modulators for the Prevention and Treatment of Dyspareunia in Postmenopausal Women Formerly held Term ended Term ended Oct 20, 2025 · High confidence | Term ended | Term ended Oct 20, 2025 | High confidence |
| US 10,478,443 | Sex Steroid Precursors Alone or in Combination with Selective Estrogen Receptor Modulators for the Prevention and Treatment of Sexual Dysfunction in Postmenopausal Women Formerly held Term ended Term ended Oct 20, 2025 · High confidence | Term ended | Term ended Oct 20, 2025 | High confidence |
| US 9,744,177 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM Lapsed on the fee record Ended Aug 29, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 29, 2025 | From the USPTO record |
| US 9,682,960 | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety Lapsed on the fee record Ended Jun 20, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 20, 2025 | From the USPTO record |